State Street Corp Makes New $1.48 Million Investment in Odyssey Therapeutics, Inc. $ODTX

Key Points

• State Street Corp initiated a $1.48 million position in Odyssey Therapeutics, acquiring 78,950 shares, while Citadel Advisors purchased a separate stake worth approximately $4.16 million.
• Odyssey Therapeutics reported a quarterly loss of $1.74 per share; analysts expect a full-year loss of $5.99 per share. The stock opened at $20.51, compared with a 12-month range of $15.10 to $29.05.
• Analyst sentiment remains mixed but leans positive, with a consensus “Moderate Buy” rating and a $35.75 target price; ratings include six Buys, one Hold, and one Sell.

State Street Corp acquired a new position in shares of Odyssey Therapeutics, Inc. (NASDAQ:ODTX - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 78,950 shares of the company's stock, valued at approximately $1,477,000. State Street Corp owned 0.16% of Odyssey Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Separately, Citadel Advisors LLC acquired a new stake in Odyssey Therapeutics in the 2nd quarter worth about $4,162,000.

Odyssey Therapeutics Stock Performance

ODTX stock opened at $20.51 on Friday. The company has a 50-day simple moving average of $22.40. Odyssey Therapeutics, Inc. has a 12 month low of $15.10 and a 12 month high of $29.05. The firm has a market cap of $985.69 million and a P/E ratio of -3.03.

Odyssey Therapeutics (NASDAQ:ODTX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.74) earnings per share (EPS) for the quarter. As a group, analysts anticipate that Odyssey Therapeutics, Inc. will post -5.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

ODTX has been the subject of several research reports. Weiss Ratings assumed coverage on Odyssey Therapeutics in a research note on Tuesday, August 11th. They set a "sell (d+)" rating for the company. JPMorgan Chase & Co. raised their target price on Odyssey Therapeutics from $26.00 to $29.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. TD Cowen started coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued a "buy" rating on the stock. Cantor Fitzgerald began coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an "overweight" rating for the company. Finally, Wall Street Zen downgraded Odyssey Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 20th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $35.75.

Odyssey Therapeutics Profile

Odyssey Therapeutics is a biotechnology company focused on discovering and developing precision medicines for immune-mediated diseases and cancer. The company combines computational biology, structural biology, medicinal chemistry and other drug-discovery technologies to identify therapies designed to target specific disease mechanisms.

Odyssey's research programs are centered on small-molecule therapeutics intended to modulate immune pathways and address conditions with significant unmet medical needs.

Want to see what other hedge funds are holding ODTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Odyssey Therapeutics, Inc. (NASDAQ:ODTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.